Azimuth Capital Investment Management’s Edwards Lifesciences EW Stock Holding History

Azimuth Capital Investment Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17.9M	Buy	223,417 +108,264	+94%	+$8.93M	0.67%	36
2025 Q4	$9.82M	Buy	+115,153	New	+$9.45M	0.35%	101
2023 Q4	–	Sell	-90,483	Closed	-$6.27M	–	304
2023 Q3	$6.27M	Sell	90,483 -2,099	-2%	-$169K	0.31%	116
2023 Q2	$8.73M	Sell	92,582 -1,693	-2%	-$147K	0.42%	77
2023 Q1	$7.8M	Sell	94,275 -2,809	-3%	-$221K	0.38%	95
2022 Q4	$7.24M	Sell	97,084 -3,559	-4%	-$274K	0.37%	98
2022 Q3	$8.32M	Sell	100,643 -793	-0.8%	-$76.3K	0.45%	70
2022 Q2	$9.65M	Buy	+101,436	New	+$10.5M	0.49%	67

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Azimuth Capital Investment Management's EW Position: Q1 2026 in Review

Azimuth Capital Investment Management increased its Edwards Lifesciences (EW) stake by 94% in Q1 2026, buying an estimated $8.93M and bringing the position to 223,417 shares worth $17.9M. The position accounts for 0.67% of the portfolio, ranked #36.

Azimuth Capital Investment Management first reported a position in EW in Q2 2022 and has held it in 8 quarters since. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Azimuth Capital Investment Management held 223,417 shares of Edwards Lifesciences worth $17.9M as of Q1 2026.
Azimuth Capital Investment Management bought 108,264 Edwards Lifesciences shares in Q1 2026, an estimated $8.93M.
Edwards Lifesciences made up 0.67% of Azimuth Capital Investment Management's portfolio in Q1 2026, its #36 holding.
Azimuth Capital Investment Management first reported a position in Edwards Lifesciences in Q2 2022 and has held it in 8 quarters since.
1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Azimuth Capital Investment Management's 13F filing for Q1 2026, filed 12 May 2026.